The Europe late-stage chronic kidney disease drugs market is expected to reach US$ 2,919.58 million by 2027 from US$ 1,256.98 million in 2019; it is estimated to grow at a CAGR of 11.3% from 2020 to 2027.
The high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policies for the late-stage chronic kidney disease treatments are among the prime factors furling the market growth in this region. However, delay in the diagnosis of chronic kidney disease hampers the growth of the market.In late-stage renal disease, kidneys lose their ability to filter waste and excess fluid from blood, which leads to waste accumulation in the body. Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. As per a research study published by the Public Library of Science (PLOS) in April 2020, CKD is estimated to have a prevalence of 2–7% in the adult German population, and the number of people opting for the targeted treatment is expected to increase with rising awareness about this condition. Moreover, the rising prevalence of hypertension and diabetes is a major cause of the progression of end-stage kidney disease (ESKD). These factors are expected to enhance market growth during the forecast period. Also, various strategies put forth by the World Health Organisation (WHO) to help policymakers in developing suitable policies, entailing the vital medicine list concept and the universal health coverage (UHC) approach, would boost the market growth in the coming years.
The COVID-19 pandemic has negatively impacted Europe late-stage chronic kidney disease drugs market. Elderly people and kidney disease patients seem to be at higher risk for more serious COVID-19 illness. However, Nephrology societies have made suggestions and provided guidelines to prevent COVID-19 transmission in dialysis facilities and to provide emergency services for patients. Therefore, the late-stage chronic kidney disease drugs market is expected to regain traction in the coming months.
Europe Late Stage Chronic Kidney Disease Drugs MarketRevenue and Forecast to 2027 (US$ Mn)
Europe Late Stage Chronic Kidney Disease Drugs MarketSegmentation
By Product Type
· Calcimimetics
· Vitamin D
· Sterols
· Potassium Binders
· Calcium-Based Phosphate Binders
By Indication
· Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
· Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
· Late Stage Chronic Kidney Disease Induced Hyperkalaemia
By Distribution Channel
· Hospital Pharmacies
· Online Pharmacies
· Retail Pharmacies
By Country
· UK
· Germany
· France
· Italy
· Spain
· Rest of Europe
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product Type, Indication, Distribution Channel, and Country
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
UK, Germany, France, Italy, Russia
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Late Stage Chronic Kidney Disease Drugs Market – By Product Type
1.3.2 Europe Late Stage Chronic Kidney Disease Drugs Market – By Indication
1.3.3 Europe Late Stage Chronic Kidney Disease Drugs Market – By Distribution Channel
1.3.4 Europe Late Stage Chronic Kidney Disease Drugs Market – By Country
2. Late Stage Chronic Kidney Disease Drugs Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Late Stage Chronic Kidney Disease Drugs Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Europe – PEST Analysis
4.3 Expert Opinion
5. Late Stage Chronic Kidney Disease Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 High Prevalence of Diseases Leading to Chronic Kidney Diseases
5.1.2 Favourable Reimbursement Policy for the Late Stage Chronic Kidney Disease Drugs
5.2 Market Restraints
5.2.1 Delay in the Diagnosis of Chronic Kidney Disease
5.3 Market Opportunities
5.3.1 Introduction of New Late Stage Chronic Kidney Disease Drugs
5.4 Future Trends
5.4.1 Introduction of New Preclinical Models to Improve Target Validation and Understand Disease Development
5.5 Impact Analysis
6. Late Stage Chronic Kidney Disease Drugs Market – Europe Analysis
6.1 Europe Late Stage Chronic Kidney Disease Drugs Market Revenue Forecast and Analysis
7. Late Stage Chronic Kidney Disease Drugs Market Analysis – By Product Type
7.1 Overview
7.2 Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Late Stage Chronic Kidney Disease Drugs by Product Type (2019 and 2027)
7.3 Calcimimetics
7.3.1 Overview
7.3.2 Calcimimetics: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Vitamin D
7.4.1 Overview
7.4.2 Vitamin D: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
7.5 Potassium Binders
7.5.1 Overview
7.5.2 Potassium Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
7.6 Calcium-Based Phosphate Binders
7.6.1 Calcium-Based Phosphate Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
7.7 Others
7.7.1 Others: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
8. Late Stage Chronic Kidney Disease Drugs Market Analysis by Indication
8.1 Overview
8.2 Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Indication (2019 and 2027)
8.3 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
8.3.1 Overview
8.3.2 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
8.4.1 Overview
8.4.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Late Stage Chronic Kidney Disease Induced Hyperkalemia
8.5.1 Overview
8.5.2 Late Stage Chronic Kidney Disease Induced Hyperkalemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9. Late Stage Chronic Kidney Disease Drugs Market Analysis by Distribution Channel
9.1 Overview
9.2 Late Stage Chronic Kidney Disease Drugs Market Share, by Distribution Channel, 2019 and 2027, (%)
9.3 Hospital Pharmacies
9.3.1 Overview
9.3.2 Hospital Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Online Pharmacies
9.4.1 Overview
9.4.2 Online Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9.5 Retail Pharmacies
9.5.1 Overview
9.5.2 Retail Pharmacies Segment: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
10. Late Stage Chronic Kidney Disease Drugs Market Analysis and Forecasts To 2027 – Europe Analysis
10.1 Europe: Late Stage Chronic Kidney Disease Drugs Market
10.1.1 Overview
10.1.2 Europe: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.3 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
10.1.4 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
10.1.5 Europe: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.1.6 Europe: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
10.1.7 Germany: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.1 Germany: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.2 Germany: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
10.1.7.3 Germany: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
10.1.7.4 Germany: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.1.8 France: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.1 France: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.2 France: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
10.1.8.3 France: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
10.1.8.4 France: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.1.9 UK: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.1 UK: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.2 UK: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
10.1.9.3 UK: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
10.1.9.4 UK: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.1.10 Italy: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.10.1 Italy: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.10.2 Italy: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
10.1.10.3 Italy: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
10.1.10.4 Italy: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
10.1.11 Spain: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.11.1 Spain: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
10.1.11.2 Spain: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
10.1.11.3 Spain: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
10.1.11.4 Spain: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
11. Impact of COVID-19 Pandemic on Europe Late Stage Chronic Kidney Disease Drugs Market
11.1 Europe: Impact Assessment of COVID-19 Pandemic
12. Company Profiles
12.1 AbbVie Inc.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Amgen
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 AstraZeneca
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Sanofi
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Kyowa Kirin Co., Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Takeda Pharmaceutical Company Limited
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Astellas Pharma Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Bayer AG
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Vifor Pharma Management Ltd.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Akebia Therapeutics, Inc.
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 Glossary of Terms
LIST OF TABLES
Table 1. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 2. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 3. Europe: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 4. Germany: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 5. Germany: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 6. Germany: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 7. France: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 8. France: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 9. France: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 10. UK: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 11. UK: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 12. UK: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 13. Italy: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 14. Italy: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 15. Italy: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 16. Spain: Late Stage Chronic Kidney Disease Drugs Market, by Product Type – Revenue and Forecast to 2027 (USD Million)
Table 17. Spain: Late Stage Chronic Kidney Disease Drugs Market, by Indication – Revenue and Forecast to 2027 (USD Million)
Table 18. Spain: Late Stage Chronic Kidney Disease Drugs Market, Distribution Channel – Revenue and Forecast to 2027 (USD Million)
Table 19. Glossary of Terms, Late Stage Chronic Kidney Disease Drugs Market
LIST OF FIGURES
Figure 1. Late Stage Chronic Kidney Disease Drugs Market Segmentation
Figure 2. Late Stage Chronic Kidney Disease Drugs Market – By Country
Figure 3. Europe Late Stage Chronic Kidney Disease Drugs Market Overview
Figure 4. Calcimimetics Segment Held Largest Share of Late Stage Chronic Kidney Disease Drugs Market
Figure 5. Europe Late Stage Chronic Kidney Disease Drugs Market- Leading Country Markets (US$ Million)
Figure 6. Europe PEST Analysis
Figure 7. Late Stage Chronic Kidney Disease Drugs Market Impact Analysis of Driver and Restraints
Figure 8. Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue Forecast and Analysis – 2019- 2027
Figure 9. Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Late Stage Chronic Kidney Disease Drugs by Product Type (2019 and 2027)
Figure 10. Calcimimetics: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 11. Vitamin D: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 12. Potassium Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 13. Calcium-Based Phosphate Binders: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 14. Others: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 15. Late Stage Chronic Kidney Disease Drugs Market Revenue Share, by Indication (2019 and 2027)
Figure 16. Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 17. Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 18. Late Stage Chronic Kidney Disease Induced Hyperkalemia: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 19. Late Stage Chronic Kidney Disease Drugs Market Share, by Distribution Channel, 2019 and 2027 (%)
Figure 20. Hospital Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 21. Online Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 22. Retail Pharmacies: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
Figure 23. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Key Country – Revenue (2019) (USD Million)
Figure 24. Europe: Late Stage Chronic Kidney Disease Drugs Market Revenue and Forecast to 2027 (USD Million)
Figure 25. Europe: Late Stage Chronic Kidney Disease Drugs Market, by Country, 2019 & 2027 (%)
Figure 26. Germany: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 27. France: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 28. UK: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 29. Italy: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 30. Spain: Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (USD Million)
Figure 31. Impact of COVID-19 Pandemic on Late Stage Chronic Kidney Disease Drugs Market in European Countries
- AbbVie Inc
- Amgen
- AstraZeneca
- Sanofi
- Kyowa Kirin Co., Ltd
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc
- Bayer AG
- Vifor Pharma Management Ltd
- Akebia Therapeutics, Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Europe Late Stage Chronic Kidney Disease Drugs Market
Jan 2021
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2021
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jan 2021
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jan 2021
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2021
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2021
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Jan 2021
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Jan 2021
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)